SR 8622
In CommitteeSenate
Rare diseases
Recognizing rare disease research and patients.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This resolution honors the work being done to understand and treat rare diseases and urges Washington residents to support those affected. It emphasizes that while each rare disease affects few people, collectively they impact millions—including about 750,000 people in Washington—and that many still lack treatments despite progress from the Orphan Drug Act.
- Commends efforts to find cures for rare diseases and recognizes the work being done by researchers, clinicians, and advocates in Washington State.
- Encourages Washington residents to acknowledge the challenges faced by people with rare diseases and their families.
- Highlights the scale of the issue—nearly 7,000 rare diseases affecting up to 30 million Americans, including about 750,000 Washingtonians.
- Notes progress made through the Orphan Drug Act, which has led to over 880 FDA-approved treatments for rare diseases, while emphasizing that many conditions still lack approved therapies.
- Raises awareness about common barriers people with rare diseases face, including delayed diagnosis, lack of specialists, and limited access to treatments and support services.
Who is affected
- Individuals with rare diseases — People living with rare diseases (estimated 750,000 in Washington) face challenges like long diagnostic delays, limited treatment options, and difficulty finding specialists.
- Families and caregivers of people with rare diseases — Families and caregivers often bear significant emotional, physical, and financial burdens while supporting loved ones with rare diseases, including funding research and advocacy efforts.
- Researchers and healthcare providers in Washington — Researchers, clinicians, and institutions in Washington—especially academic medical centers and biotech/pharma companies—play a leading role in developing treatments and cures for rare diseases.
- State government agencies — State government may be called on to support rare disease initiatives through policy, data collection, or coordination with federal programs, though this resolution does not mandate new spending or programs.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Formal recognition of the scale and impact of rare diseases in Washington may catalyze state-level policy attention, improve data collection, and strengthen advocacy—potentially leading to future investments in diagnostics, specialist networks, and treatment access.
HealthcarePeopleRef: WHEREAS clause on 750,000 Washingtonians affected and 'commit to a future of hope through compassionate care'Public commendation may bolster morale and visibility for Washington’s rare disease research ecosystem—including academic medical centers and biotech firms—which could attract talent, partnerships, and federal grants, indirectly supporting high-skilled jobs.
Business & EmploymentPeopleRef: WHEREAS clause commending researchers, clinicians, and advocates in WashingtonIncreased public awareness may reduce stigma, improve community support, and encourage early reporting of symptoms—potentially shortening diagnostic odysseys and enabling earlier intervention for vulnerable individuals.
Public SafetyPeopleRef: WHEREAS clause encouraging Washingtonians to recognize the struggle of those affected and their familiesHighlighting the success of the Orphan Drug Act may reinforce political will to sustain and expand federal incentives for rare disease drug development—benefiting patients by accelerating pipeline growth.
HealthcarePeopleRef: WHEREAS clause on the Orphan Drug Act leading to over 880 FDA-approved treatmentsFormal legislative acknowledgment affirms the dignity and lived experience of people with rare diseases—reinforcing societal inclusion and potentially strengthening legal arguments for reasonable accommodations under existing disability laws.
Rights & LibertiesLean peopleRef: WHEREAS clause on 'thousands of residents of Washington are among those affected'
Potential Concerns (3)
This resolution raises awareness about barriers to care for people with rare diseases, but contains no binding provisions to improve access, reduce diagnostic delays, or expand coverage—leaving structural challenges unaddressed despite heightened visibility.
HealthcareRef: WHEREAS clauses on delayed diagnosis, lack of specialists, and limited access to treatmentsThe resolution acknowledges that families often fund research and advocacy themselves, but offers no financial relief or institutional support to offset these out-of-pocket costs—reinforcing an inequitable burden on already-strained households.
FinancialRef: WHEREAS clause on families bearing 'a large share of the burden of funding research and raising public awareness'While the resolution expresses support, it imposes no new responsibilities or funding obligations on state agencies or local governments, limiting its practical impact on public systems—even as it may raise expectations for future action.
Local GovernmentRef: Entire resolution (no fiscal impact, no mandates, no funding)
Who Is Most Affected
Individuals with rare diseases gain symbolic recognition and may benefit from increased political attention and future policy action, but the resolution itself provides no direct healthcare, financial, or legal protections.
Families and caregivers may experience reduced isolation and increased community empathy, but continue bearing financial and emotional burdens without new support mechanisms.
Washington-based researchers and biotech/pharma firms gain public goodwill and political legitimacy, which may aid grant applications and partnerships—but the resolution does not allocate new research funding.
State agencies may face increased informal pressure to coordinate with federal rare disease initiatives or support data collection, but no new duties or funding are mandated.